Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025
Protagonist Therapeutics has been named to Fast Company's World's Most Innovative Companies for 2025, securing a position among the top 5 Most Innovative Biotechnology companies. The recognition highlights their pioneering work in peptide-based drug development.
The company's achievements include multiple breakthrough candidates:
- Rusfertide: A hepcidin mimetic with successful Phase 3 trials for polycythemia vera, developed with Takeda Pharmaceuticals
- Icotrokinra (JNJ-2113): The first oral IL-23 receptor antagonist, showing efficacy in Phase 3 psoriasis trials and Phase 2 ulcerative colitis trials
- PN-881: An oral IL-17 antagonist advancing to first-in-human trials
- An anti-obesity program focusing on oral alternatives to injectables
The company maintains strong financial health with a cash runway through at least 2028. Both Rusfertide and Icotrokinra are expected to file NDAs with the FDA this year.
Protagonist Therapeutics è stata nominata tra le aziende più innovative del mondo secondo Fast Company per il 2025, assicurandosi una posizione tra le prime 5 aziende di biotecnologia più innovative. Questo riconoscimento mette in evidenza il loro lavoro pionieristico nello sviluppo di farmaci a base di peptidi.
I risultati dell'azienda includono diversi candidati innovativi:
- Rusfertide: Un mimetico della hepcidina con trial di Fase 3 di successo per la policitemia vera, sviluppato con Takeda Pharmaceuticals
- Icotrokinra (JNJ-2113): Il primo antagonista orale del recettore IL-23, che ha mostrato efficacia nei trial di Fase 3 per la psoriasi e nei trial di Fase 2 per la colite ulcerosa
- PN-881: Un antagonista orale dell'IL-17 che sta avanzando verso i trial di prima somministrazione nell'uomo
- Un programma anti-obesità che si concentra su alternative orali agli iniettabili
L'azienda mantiene una solida salute finanziaria con una cassa disponibile fino almeno al 2028. Sia Rusfertide che Icotrokinra si aspettano di presentare NDA alla FDA quest'anno.
Protagonist Therapeutics ha sido nombrada entre las empresas más innovadoras del mundo por Fast Company para 2025, asegurando una posición entre las 5 empresas de biotecnología más innovadoras. Este reconocimiento destaca su trabajo pionero en el desarrollo de fármacos basados en péptidos.
Los logros de la empresa incluyen múltiples candidatos innovadores:
- Rusfertide: Un mimético de hepcidina con ensayos de Fase 3 exitosos para la policitemia vera, desarrollado con Takeda Pharmaceuticals
- Icotrokinra (JNJ-2113): El primer antagonista oral del receptor IL-23, que muestra eficacia en ensayos de Fase 3 para la psoriasis y ensayos de Fase 2 para la colitis ulcerosa
- PN-881: Un antagonista oral de IL-17 que avanza a ensayos de primera administración en humanos
- Un programa antiobesidad centrado en alternativas orales a los inyectables
La empresa mantiene una sólida salud financiera con un capital disponible hasta al menos 2028. Se espera que tanto Rusfertide como Icotrokinra presenten NDA a la FDA este año.
Protagonist Therapeutics는 2025년 패스트 컴퍼니의 세계에서 가장 혁신적인 기업 중 하나로 선정되어, 가장 혁신적인 생명공학 회사 5위 안에 이름을 올렸습니다. 이 인정은 펩타이드 기반 약물 개발에서 그들의 선구적인 작업을 강조합니다.
회사의 성과에는 여러 혁신적인 후보가 포함됩니다:
- Rusfertide: 다발적 적혈구증가증을 위한 성공적인 3상 임상 시험을 가진 헤프시딘 모사체로, 타케다 제약과 함께 개발되었습니다.
- Icotrokinra (JNJ-2113): 3상 건선 임상 시험과 2상 궤양성 대장염 임상 시험에서 효능을 보여준 최초의 경구 IL-23 수용체 길항제입니다.
- PN-881: 인간에 대한 첫 번째 임상 시험으로 진행 중인 경구 IL-17 길항제입니다.
- 주사제의 경구 대안을 중심으로 한 비만 방지 프로그램입니다.
회사는 2028년까지의 자금 조달을 유지하며, Rusfertide와 Icotrokinra는 올해 FDA에 NDA를 제출할 것으로 예상됩니다.
Protagonist Therapeutics a été nommé parmi les entreprises les plus innovantes au monde par Fast Company pour 2025, se classant parmi les 5 entreprises de biotechnologie les plus innovantes. Cette reconnaissance met en avant leur travail pionnier dans le développement de médicaments à base de peptides.
Les réalisations de l'entreprise incluent plusieurs candidats révolutionnaires :
- Rusfertide : Un mimétique de l'hépcidine avec des essais de Phase 3 réussis pour la polycythémie vraie, développé avec Takeda Pharmaceuticals
- Icotrokinra (JNJ-2113) : Le premier antagoniste oral du récepteur IL-23, montrant une efficacité dans les essais de Phase 3 pour le psoriasis et les essais de Phase 2 pour la colite ulcéreuse
- PN-881 : Un antagoniste oral de l'IL-17 avançant vers les essais chez l'homme
- Un programme anti-obésité axé sur des alternatives orales aux injectables
L'entreprise maintient une solide santé financière avec une caisse disponible jusqu'au moins en 2028. Tant Rusfertide qu'Icotrokinra devraient déposer des NDA auprès de la FDA cette année.
Protagonist Therapeutics wurde unter den innovativsten Unternehmen der Welt von Fast Company für 2025 ausgezeichnet und sicherte sich einen Platz unter den Top 5 der innovativsten Biotechnologieunternehmen. Diese Anerkennung hebt ihre bahnbrechende Arbeit in der Entwicklung von peptidbasierten Arzneimitteln hervor.
Die Erfolge des Unternehmens umfassen mehrere bahnbrechende Kandidaten:
- Rusfertide: Ein Hepcidin-Mimetikum mit erfolgreichen Phase-3-Studien für Polycythaemia vera, entwickelt in Zusammenarbeit mit Takeda Pharmaceuticals
- Icotrokinra (JNJ-2113): Der erste orale IL-23-Rezeptorantagonist, der in Phase-3-Studien zur Psoriasis und Phase-2-Studien zur Colitis ulcerosa Wirksamkeit zeigt
- PN-881: Ein oraler IL-17-Antagonist, der in die erste menschliche Studie übergeht
- Ein Anti-Adipositas-Programm, das sich auf orale Alternativen zu Injektionsmitteln konzentriert
Das Unternehmen hat eine starke finanzielle Gesundheit mit einer Liquidität bis mindestens 2028. Sowohl Rusfertide als auch Icotrokinra werden voraussichtlich in diesem Jahr NDA bei der FDA einreichen.
- None.
- None.
Past Winners include Waymo, Nvidia, Duolingo, and Novo Nordisk, among others
NEWARK, CALIFORNIA / ACCESS Newswire / March 18, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company"), a clinical-stage biopharmaceutical company pioneering the discovery and development of peptide-based therapeutics, today announced its inclusion in Fast Company's prestigious annual list of the World's Most Innovative Companies for 2025.
Fast Company's annual list of the World's Most Innovative Companies spotlights organizations across various industries that are driving meaningful change through groundbreaking ideas and transformative technologies. The 2025 edition highlights businesses leading the way in sustainability, healthcare, artificial intelligence, and more.
Protagonist has been recognized as a Most Innovative Company and a top 5 Most Innovative Biotechnology company for its groundbreaking work in peptide-based drug development that led to the creation of multiple differentiated, first-in-class, and best-in-class assets targeting validated disease pathways. The company's peptide-based therapeutics offer the potential for targeted, orally administered solutions for diseases that have historically required injectable treatments as well as highly differentiated therapies for patients with unmet medical needs. As a public company, Protagonist's strategic aims include strong balance sheet management, and the company currently has a cash runway through at least the end of 2028.
The company's peptide development platform has successfully delivered multiple candidates, including:
Rusfertide, a mimetic of the hormone hepcidin that recently had a successful outcome in a Phase 3 trial for the potential treatment of the rare disease polycythemia vera. Rusfertide is being jointly developed with Takeda Pharmaceuticals and is moving towards an NDA filing with the FDA this year.
Icotrokinra (JNJ-2113), the first-ever oral IL-23 receptor antagonist developed in collaboration with Johnson & Johnson, which has shown substantial efficacy in multiple Phase 3 trials for psoriasis and a Phase 2 trial for ulcerative colitis, and has potential to transform the treatment paradigm for these disease indications. An NDA filing of icotrokinra for psoriasis is expected this year.
PN-881, an oral IL-17 antagonist with potential best-in-class properties, is moving towards first-in-human trials.
An anti-obesity program aimed at providing oral drugs in a market currently dominated by injectables.
"Our list of the Most Innovative Companies offers a comprehensive look at innovation today and a playbook for the future," said Fast Company editor-in-chief Brendan Vaughan. "This year, we recognize companies that are harnessing AI in deep and meaningful ways, brands that are turning customers into superfans by overdelivering for them, and challengers that are introducing bold ideas and vital competition to their industries. At a time when the world is rapidly shifting, these companies are charting the way forward."
"Being named to Fast Company's Most Innovative Companies list is a testament to the relentless dedication of our team and our mission to bring truly differentiated peptide therapeutics to patients," said Dinesh V. Patel, Ph.D., President and CEO of Protagonist Therapeutics. "With the recent announcement of positive late-stage data from our two homegrown assets and a robust pipeline of next-generation candidates, we remain at the forefront of scientific innovation in immunology, hematology, and metabolic diseases. Our work is driven by the pursuit of life-changing therapies, and we are honored to be recognized for these efforts."
The full list of Fast Company's Most Innovative Companies honorees can now be found at fastcompany.com. It will also be available on newsstands beginning March 25.
About Protagonist
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides, icotrokinra and rusfertide, derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA expected in 2025. Icotrokinra (JNJ-2113) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor ("IL-23R") which is licensed to Janssen Biotech, Inc., a Johnson & Johnson company. Following icotrokinra's joint discovery by Protagonist and Johnson & Johnson scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with Johnson & Johnson assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered into in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage oral drug discovery programs addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.
More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at www.protagonist-inc.com .
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the expected timing of regulatory filings and the potential benefits of our discovery candidates. In some cases, you can identify these statements by forward-looking words such as "anticipate," "believe," "may," "will," "expect," or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, our ability to earn milestone payments under our collaboration agreements with Janssen and Takeda, our ability to use and expand our programs to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, and our ability to obtain and adequately protect intellectual property rights for our product candidates. Additional information concerning these and other risk factors affecting our business can be found in our periodic filings with the Securities and Exchange Commission, including under the heading "Risk Factors" contained in our most recently filed periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.
Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com
Media Contact
Virginia Amann, Founder/CEO
ENTENTE Network of Companies
+1 833 500 0061 ext 1
virginiaamann@ententeinc.com
SOURCE: Protagonist Therapeutics
View the original press release on ACCESS Newswire
FAQ
What major clinical trials has PTGX completed in 2025?
When will PTGX submit FDA applications for Rusfertide and Icotrokinra?
How long will PTGX's current cash reserves last?
What are the key drug candidates in PTGX's development pipeline?
What makes PTGX's Icotrokinra (JNJ-2113) unique in the market?
